Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.On November 14, Austin-based Saturn V Capital Management disclosed a significant purchase of Amylyx Pharmaceuticals stock (AMLX 3.73%) that helped increase its position by $41.7 million quarter-over-quarter.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Saturn V Capital Management LP increased its stake in Amylyx Pharmaceuticals (AMLX 3.73%) by 1 ...

Core Insights - MPM BioImpact fully divested its position in MoonLake Immunotherapeutics, selling 313,571 shares and reducing exposure by approximately $14.8 million, which previously constituted 2.6% of its assets under management [2][7] - MoonLake's stock experienced a dramatic decline of nearly 90% in a single day due to mixed Phase 3 trial results for its investigational therapy, sonelokimab, leading to a class-action lawsuit and significant market value loss [6][9] - As of the latest market close, MoonLake's shares were priced at $13.80, reflecting a 74% decrease from the previous year, while the S&P 500 index increased by 13% during the same period [3][4] Company Overview - MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biotechnology company focused on developing sonelokimab, a Nanobody therapy aimed at treating inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis [5] - The company operates a clinical-stage biopharmaceutical model, investing in research and development to advance its pipeline through clinical trials, with future revenue dependent on successful product commercialization and regulatory approval [5] Financial Metrics - As of the latest report, MoonLake's market capitalization stands at $977.7 million, with a net income of -$210.5 million over the trailing twelve months [4] - The company reported $380.5 million in cash, projecting a financial runway into the second half of 2027, and is preparing for a crucial FDA meeting on December 15 to evaluate its evidence package for sonelokimab [8]

Core Viewpoint - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is advancing its Phase 3 clinical trial for MASH, which is crucial for its mission to provide therapeutic solutions for patients [1] Financial Performance - On September 25, 2025, Inventiva reported an earnings per share (EPS) of -$0.64, which was below the estimated EPS of -$0.41, while generating revenue of approximately $5.24 million, slightly surpassing estimates [2][6] - The company has secured a €116 million tranche of structured financing, enhancing its financial position with cash and cash equivalents totaling €146.7 million as of June 30, 2025, ensuring a cash runway until the end of the third quarter of 2026 [3][6] Financial Metrics - Inventiva's financial metrics indicate a challenging environment, with a price-to-earnings (P/E) ratio of approximately -1.46, reflecting negative earnings, and a price-to-sales ratio of about 33.51, indicating that investors are paying $33.51 for every dollar of sales [4][6] - The enterprise value to sales ratio is approximately 28.92, showing the company's valuation relative to its sales [4] - The debt-to-equity ratio is about -0.51, indicating more liabilities than equity, and the current ratio of approximately 0.92 suggests potential difficulty in covering short-term liabilities with short-term assets [5][6]

Core Viewpoint - Altimmune, Inc. has appointed Jerry Durso as Chairman of the Board, succeeding Mitchel Sayare, as the company prepares for Phase 3 development of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) [1][2][3] Group 1: Leadership Transition - The leadership change is part of the Board's succession planning and aligns with the company's advancement into Phase 3 development of pemvidutide [2] - Jerry Durso has over 30 years of leadership experience in the life sciences industry, with expertise in corporate and commercial strategy [3] - Mitchel Sayare will continue to serve on the Board as an Independent Director after his tenure as Chairman [1][3] Group 2: Pemvidutide Development - Altimmune's lead program, pemvidutide, is a GLP-1/glucagon dual receptor agonist aimed at treating MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [4] - The company expects to hold an End-of-Phase 2 Meeting with the FDA for MASH in the fourth quarter of 2025 [2] Group 3: Company Background - Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [4]